One Global Service Provider sets Sep 29 AGM for dividend, acquisition
- One Global Service Provider schedules 34th AGM for September 29, 2026
- Final dividend of ₹1 per share recommended for FY26, subject to approval
- Preferential issue of 7,15,040 shares at ₹553 each for acquisition
- Related-party transaction limit with Lifenity Health set at ₹500 crore for FY27

*this image is generated using AI for illustrative purposes only.
One Global Service Provider has scheduled its 34th Annual General Meeting (AGM) for September 29, 2026, to approve a final dividend of ₹1 per share for FY26 and sanction a major strategic acquisition via a preferential issue. The meeting will also seek shareholder consent for significant related-party transactions and enhanced borrowing limits.
Financial Performance and Dividend
The company reported a robust financial performance for FY26, driven by the amalgamation of Plus Care Internationals Private Limited. Total revenue surged to ₹49,881.06 lakh, up from ₹14,784.17 lakh in FY25. Profit after tax (PAT) more than tripled to ₹6,950.42 lakh from ₹1,846.66 lakh in the previous year.
The Board of Directors has recommended a final dividend of ₹1 per equity share (face value ₹10), representing a 10% payout. This is subject to shareholder approval at the AGM. The record date for both the dividend payment and voting eligibility is September 22, 2026.
| Metric | FY26 | FY25 | Growth |
|---|---|---|---|
| Total Revenue | ₹49,881.06 lakh | ₹14,784.17 lakh | +237.5% |
| Profit After Tax | ₹6,950.42 lakh | ₹1,846.66 lakh | +276.4% |
| Net Worth | ₹14,122.84 lakh | ₹7,172.42 lakh | +96.9% |
Strategic Acquisition and Preferential Issue
A key agenda item is the proposed acquisition of a 51% stake in Matrix Labs Diagnocare Private Limited (MLDPL) and Matrix Labs Private Limited (MLPL). To facilitate this, the company plans to issue 7,15,040 equity shares on a preferential basis for consideration other than cash.
The issue price is set at ₹553 per share, based on the volume-weighted average price over the 10 trading days preceding the relevant date of August 28, 2026. The total non-cash consideration amounts to approximately ₹39.54 crore. The allottees include Mr. Suresh and Ms. Nithya S for MLDPL, and Mr. Suresh for MLPL.
Related Party Transactions and Borrowing Limits
The AGM will also approve material related-party transactions with Lifenity Health Limited (LHL), where the Managing Director serves as a non-executive director. The proposed transaction limit is ₹500 crore for FY27, covering the purchase and sale of goods, services, and assets. In FY26, sales to LHL totaled ₹16,321.21 lakh.
Additionally, shareholders are asked to approve:
- An increase in authorized share capital from ₹25.05 crore to ₹50 crore.
- Overall borrowing limits under Section 180(1)(c) of the Companies Act, 2013, up to the aggregate of paid-up capital, free reserves, and securities premium or ₹1,000 crore, whichever is higher.
- Re-appointment of Mr. Sanjay Upadhaya as Managing Director and M/s. S D P M & Co. as Statutory Auditors for a second five-year term.
What the Numbers Show
The dramatic expansion in revenue and PAT underscores the impact of the Plus Care Internationals merger. However, trade receivables have risen sharply to ₹21,657.79 lakh from ₹5,406.14 lakh in FY25, while cash and cash equivalents declined to ₹1,570.63 lakh from ₹2,714.72 lakh. This divergence suggests that while top-line growth is strong, working capital management and collection cycles will be critical areas to monitor as the company scales its operations through new acquisitions.
Historical Stock Returns for One Global Service Provider
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.76% | -4.52% | 0.0% | 0.0% | 0.0% | 0.0% |
How will the acquisition of Matrix Labs Diagnocare and Matrix Labs Private Limited impact One Global Service Provider's revenue mix and profitability margins in FY27?
Given the sharp rise in trade receivables to ₹21,657.79 lakh, what specific credit risk mitigation strategies will the company implement to protect cash flow?
What is the strategic rationale behind the proposed ₹500 crore related-party transaction limit with Lifenity Health Limited, and how does it compare to historical transaction volumes?


































